KRRO Quote, Financials, Valuation and Earnings

Gilead Sciences, Inc. has a net margin of -1656.97% compared to Korro Bio, Inc.'s net margin of 39.21%. Korro Bio, Inc.'s return on equity of -63.78% beat Gilead Sciences, Inc.'s return on equity of 41.48%.

Korro Bio, Inc. has a consensus price target of $93.88, signalling upside risk potential of 516.1%. On the other hand Gilead Sciences, Inc. has an analysts' consensus of $130.63 which suggests that it could grow by 7.77%. Given that Korro Bio, Inc. has higher upside potential than Gilead Sciences, Inc., analysts believe Korro Bio, Inc. is more attractive than Gilead Sciences, Inc..

Korro Bio, Inc. has a beta of 3.030, which suggesting that the stock is 203.009% more volatile than S&P 500. In comparison Gilead Sciences, Inc. has a beta of 0.318, suggesting its less volatile than the S&P 500 by 68.175%.

Korro Bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Gilead Sciences, Inc. offers a yield of 2.59% to investors and pays a quarterly dividend of $0.79 per share. Korro Bio, Inc. pays -- of its earnings as a dividend. Gilead Sciences, Inc. pays out 805.23% of its earnings as a dividend.

Korro Bio, Inc. quarterly revenues are $1.1M, which are smaller than Gilead Sciences, Inc. quarterly revenues of $7.8B. Korro Bio, Inc.'s net income of -$18.1M is lower than Gilead Sciences, Inc.'s net income of $3.1B. Notably, Korro Bio, Inc.'s price-to-earnings ratio is -- while Gilead Sciences, Inc.'s PE ratio is 18.78x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Korro Bio, Inc. is 8.94x versus 5.24x for Gilead Sciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Nutriband, Inc. has a net margin of -1656.97% compared to Korro Bio, Inc.'s net margin of -321.33%. Korro Bio, Inc.'s return on equity of -63.78% beat Nutriband, Inc.'s return on equity of -117.44%.

Korro Bio, Inc. has a consensus price target of $93.88, signalling upside risk potential of 516.1%. On the other hand Nutriband, Inc. has an analysts' consensus of $15.00 which suggests that it could grow by 211.2%. Given that Korro Bio, Inc. has higher upside potential than Nutriband, Inc., analysts believe Korro Bio, Inc. is more attractive than Nutriband, Inc..

Korro Bio, Inc. has a beta of 3.030, which suggesting that the stock is 203.009% more volatile than S&P 500. In comparison Nutriband, Inc. has a beta of 1.907, suggesting its more volatile than the S&P 500 by 90.735%.

Korro Bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nutriband, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Korro Bio, Inc. pays -- of its earnings as a dividend. Nutriband, Inc. pays out -- of its earnings as a dividend.

Korro Bio, Inc. quarterly revenues are $1.1M, which are larger than Nutriband, Inc. quarterly revenues of $622.5K. Korro Bio, Inc.'s net income of -$18.1M is lower than Nutriband, Inc.'s net income of -$2M. Notably, Korro Bio, Inc.'s price-to-earnings ratio is -- while Nutriband, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Korro Bio, Inc. is 8.94x versus 20.81x for Nutriband, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals, Inc. has a net margin of -1656.97% compared to Korro Bio, Inc.'s net margin of 38.89%. Korro Bio, Inc.'s return on equity of -63.78% beat Regeneron Pharmaceuticals, Inc.'s return on equity of 15.37%.

Korro Bio, Inc. has a consensus price target of $93.88, signalling upside risk potential of 516.1%. On the other hand Regeneron Pharmaceuticals, Inc. has an analysts' consensus of $781.13 which suggests that it could grow by 8.74%. Given that Korro Bio, Inc. has higher upside potential than Regeneron Pharmaceuticals, Inc., analysts believe Korro Bio, Inc. is more attractive than Regeneron Pharmaceuticals, Inc..

Korro Bio, Inc. has a beta of 3.030, which suggesting that the stock is 203.009% more volatile than S&P 500. In comparison Regeneron Pharmaceuticals, Inc. has a beta of 0.369, suggesting its less volatile than the S&P 500 by 63.095%.

Korro Bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals, Inc. offers a yield of 0.49% to investors and pays a quarterly dividend of $0.88 per share. Korro Bio, Inc. pays -- of its earnings as a dividend. Regeneron Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Korro Bio, Inc. quarterly revenues are $1.1M, which are smaller than Regeneron Pharmaceuticals, Inc. quarterly revenues of $3.8B. Korro Bio, Inc.'s net income of -$18.1M is lower than Regeneron Pharmaceuticals, Inc.'s net income of $1.5B. Notably, Korro Bio, Inc.'s price-to-earnings ratio is -- while Regeneron Pharmaceuticals, Inc.'s PE ratio is 17.20x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Korro Bio, Inc. is 8.94x versus 5.56x for Regeneron Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Vertex Pharmaceuticals, Inc. has a net margin of -1656.97% compared to Korro Bio, Inc.'s net margin of 34.76%. Korro Bio, Inc.'s return on equity of -63.78% beat Vertex Pharmaceuticals, Inc.'s return on equity of 22.13%.

Korro Bio, Inc. has a consensus price target of $93.88, signalling upside risk potential of 516.1%. On the other hand Vertex Pharmaceuticals, Inc. has an analysts' consensus of $487.28 which suggests that it could grow by 6.98%. Given that Korro Bio, Inc. has higher upside potential than Vertex Pharmaceuticals, Inc., analysts believe Korro Bio, Inc. is more attractive than Vertex Pharmaceuticals, Inc..

Korro Bio, Inc. has a beta of 3.030, which suggesting that the stock is 203.009% more volatile than S&P 500. In comparison Vertex Pharmaceuticals, Inc. has a beta of 0.318, suggesting its less volatile than the S&P 500 by 68.249%.

Korro Bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vertex Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Korro Bio, Inc. pays -- of its earnings as a dividend. Vertex Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Korro Bio, Inc. quarterly revenues are $1.1M, which are smaller than Vertex Pharmaceuticals, Inc. quarterly revenues of $3.1B. Korro Bio, Inc.'s net income of -$18.1M is lower than Vertex Pharmaceuticals, Inc.'s net income of $1.1B. Notably, Korro Bio, Inc.'s price-to-earnings ratio is -- while Vertex Pharmaceuticals, Inc.'s PE ratio is 32.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Korro Bio, Inc. is 8.94x versus 10.06x for Vertex Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.